Quinoline derivatives as EP4 antagonists

A compound according to the following formula:

• or a pharmaceutically acceptable salt thereof, wherein:
• A is N,
• B is CH;
• Y and Z are CH;
• Q is C;
• R1 and R2 are independently selected from the group consisting of:
• C1-6alkoxy, C1-6fluoroalkoxy, C3-6cycloalkoxy, C3 -6cycloalkylmethoxy, and C1 -6perfluoroalkoxy;
• R3 and R4 are independently selected from the group consisting of:
• H, halogen, C1-6alkyl, C3 -6cycloalkyl, C1-6fluoroalkyl, C1-6alkoxy, C1-6fluoroalkoxy, C3 -6cycloalkoxy, C3 -6cycloalkylmethoxy, NH2, —NHC1-4alkyl, —N(C1-4alkyl)2, NO2, OH and CN;
• R7 to R10 are H;
• R11 is selected from the group consisting of:
• (a) C1-6alkyl, (b) C3-6cycloalkyl, (c) C3-6cycloalkyl substituted by one to three substituents independently selected from R12;
• (d) aryl, (e) aryl substituted by one to three substituents independently selected from R12, (f) heteroaryl, (g) heteroaryl substituted by one to three substituents independently selected from R12, (h) heterocyclyl, (i) heterocyclyl substituted by one to three substituents independently selected from R12, (j) —C1-6alkylaryl, (k) —C1-6alkylaryl substituted by one to five substituents independently selected from R12, (k) —C1-6alkyl-C3-6cycloalkyl;
• (l) —C1-6alkyl-C3-6cycloalkyl substituted by one to five substituents independently selected from R12;
• (m) —C1-6alkylhetereoaryl;
• (n) —C1 -6alkylheteroaryl substituted by one to five substituents independently selected from R12;
• (o) —C1 -6alkylheterocyclyl;
• and (p) —C1-6alkylheterocyclyl substituted by one to five substituents independently selected from R12;
• and fused analogs of (b) to (p);
• and
• R12 is selected from the group consisting of:
• halogen, C1-6alkyl, C1-6fluoroalkyl, C3-6cycloalkyl, C1-6alkoxy, C1-6fluoroalkoxy, C3-6cycloalkoxy, NH2, —NHC 1-4alkyl or —N(C1-4alkyl)2, NO2 and OH, or two R12 groups attached to the same atom may be joined together to form a Spiro C3 -6cycloalkyl group.